| INTRODUCTION
Clinical mastitis (CM) is still a common and costly disease on dairy farms all over the world (IDF (International Dairy Federation), 2005; Hogeveen, Huijps, & Lam, 2011) . The treatment method of choice to combat CM is antibiotic therapy, which was confirmed by a recently conducted multiherd study on Dutch dairy farms. Santman-Berends, Lam, Keurentjes, and van Schaik (2015) showed that in 72% of CM cases, farmers decided to use antibiotic treatment. Other investigations conducted in 51 large dairy herds in Wisconsin, USA, reported that 95.4% of cows suffering from CM were treated with antibiotics (Oliveira & Ruegg, 2014) . This results in high usage of antibiotics, which is currently publicly discussed due to the problem of residuals and potential development of pathogen resistances. Cows suffering from CM should be supplied with evidence-based treatment to ensure prudent use of antibiotics (Mansion-de Vries, Hoedemaker, & Krömker, 2015; Ruegg, 2010) because it is impossible to prevent all CM cases. Trevisi et al. (2014) mentioned that antibiotic treatments for chronic disease cases do not lead to increased animal health and are not reasonable with regard to cost/benefit analysis. The aim of antibiotic therapy must be considered to determine the benefit of antibiotics for such chronic disease cases. Antibiotics are only able to combat micro-organisms. Therefore, the success is assessed by bacteriological cure (BC) and is defined as the elimination of the mastitiscausing pathogen from the infected udder quarter (Krömker, Paduch, Klocke, Friedrich, & Zinke, 2010; Schukken et al., 2013; Swinkels, Krömker, & Lam, 2014; Ziesch & Krömker, 2016) . Many studies dealt with the influence of cow-related factors on the BC rate of CM cases treated with antibiotics. The investigations showed a decreasing probability of BC with rising amount of previous CM cases in the same lactation (Pinzón-Sánchez & Ruegg, 2011; Ziesch & Krömker, 2016) and high cow somatic cell counts (CSCC) prior to CM (Bradley & Green, 2009; Pinzón-Sánchez & Ruegg, 2011; Sol, Sampimon, Barkema, & Schukken, 2000; Swinkels, Cox, Schukken, & Lam, 2013; Ziesch & Krömker, 2016) . Consequently, lowering the likelihood of BC results in declining efficacy and usefulness of antibiotic treatment. Cows with longer lasting udder diseases are characterized by recurrent CM cases separated by periods without clinical signs and/or constantly elevated CSCC defined as subclinical mastitis (Grieger, Zoche-Golob, Paduch, Hoedemaker, & Krömker, 2014; GVA [German Veterinary Association], 2012) . With the help of the aforementioned cow-related factors, CM history in the current lactation and persistent elevation in CSCC, we are able to determine cows expecting a low probability of BC due to antibiotic treatment. If possible such cows should be removed from the herd (Krömker & Friedrich, 2011) or in the case of CM be treated symptomatically to avoid useless application of antibiotics (Degen, Paduch, Hoedemaker, & Krömker, 2015) . From a farmer's point of view, such cows, especially the high-yielding animals, are still profitable as long as they show no clinical signs and the milk is saleable. In the case of CM, a low likelihood of BC is expected from a scientific point of view. Maybe an equal clinical cure (CC) rate and recurrence rate during the further course of lactation in comparison with an antibiotic treatment could possibly convince farmers to use an alternative therapy. The medicinal product Masti Veyxym ® (Veyx-Pharma GmbH, Schwarzenborn, Germany), an already licensed udder injector containing ointment for intramammary application with proteolytic enzymes and without antibiotics, could be a useful treatment option. In vitro investigations showed an inhibiting activity of containing proteolytic enzymes against udder pathogens (Krüger, Hien, Zaremba, & Penka, 1999 
| MATERIALS AND METHODS

| Study design
This study was conducted in accordance with the guidelines on good clinical practice (GCP; EMEA (The European Agency for the Evaluation of Medicinal Products), 2000) and designed as a noninferiority study to compare two test treatment groups with one reference treatment group by a previously defined margin of noninferiority (∆; Piaggio, Elbourne, Altman, Pocock, & Evans, 2009; O`Connor et al., 2010; Schukken et al., 2013) . The null hypothesis implied that the test product is inferior to the reference product, and the alternative hypothesis implied that the test product is not inferior to the reference product regarding the defined margin (−∆; Piaggio et al., 2009; Schukken et al., 2013) :
Whereby, P outcome is the probability of outcome variables for the test and reference product. To establish noninferiority of a test product to a reference product, the null hypothesis (H 0 ) must be discarded to accept the alternative hypothesis (H A ). The evaluations of possible study results that were described by Schukken et al. (2013) also apply for this study.
| Sample size determination
Based on investigations of Schukken et al. (2011) , the margin of noninferiority (∆) was determined as 0.15 for this study. Also, other investigators recommended and applied this value for noninferiority margin in CM studies (Deluyker, Chester, & van Oye, 1999; Schukken & Deluyker, 1995; Schukken et al., 2013) . The confidence interval (CI; 95%) approach was used to calculate required sample size based on the clinical cure rate and CM recurrence rate. In this model, treatments are assumed to achieve similar cure and recurrence rates and we want to assure on the 95% level that the difference is not higher than 15% regarding the margin of noninferiority and the null effect.
If there is truly no difference in clinical cure rates between the reference and test treatment, then 37 CM cases per group are required so as to be 90% sure that the upper limit of a one-sided 95%
CI rules out a difference in favour of the reference group of more than 15%.
If there is truly no difference in recurrence rates between the reference and test treatment, then 50 CM cases per group are required so as to be 80% sure that the upper limit of a one-sided 95% CI rules out a difference in favour of the reference group of more than 15%.
Using the estimation of the recurrences due to the higher required sample size, we calculated that if a further 10%-15% of CM cases drop out of the study postadmission, around 60 cases are needed per treatment group. Therefore, a total of 180 cows with CM have to be included.
| Inclusion criteria for farms and cows
Commercial dairy free-stall farms with interest in and possibilities for performing the study were eligible for inclusion. Study farms have to participate in the German Dairy Herd Improvement (DHI) programme, which records cow data, CSCC, milk yield and milk ingredients on a monthly basis.
Every cow must be registered with a unique ear tag to clearly identify every animal, as stipulated in Germany. Only cows that have had at least three consecutively high CSCC (> 400,000 somatic cells/ ml) in the three previous months and/or at least two CM cases in the current lactation directly before the occurrence of the CM were admitted for inclusion in the study. Lactating Holstein-Friesian dairy cows of all parities with CM signs in one or more quarters were eligible for inclusion. Suitable cows showed a period of normal milk secretion without signs of inflammation on the udder quarters until start of CM. The subsequent clinical score was used to characterize and determine CM at occurrence. A quarter was classified as affected by a mild CM if there were only changes in the appearance of the milk (i.e., flaky sediments, watery appearance, discolouration).
A moderate CM showed additionally clinical signs of mastitis in the quarter (i.e., swelling, heat, pain, redness) with or without changes in milk secretion as previously described. A CM was classified as severe when a cow suffered from general clinical signs of disease (i.e., fever (rectal temperature >39.5°C), dehydration, anorexia, depression) with or without deviations of the milk and/or the udder quarter (Pinzón-Sánchez & Ruegg, 2011; Swinkels et al., 2014) . Cows were excluded from the study if they showed significant udder, teat or teat orifice lesions, suffered from severe CM cases, had been treated with other products in addition to the mastitis treatment or had concurrent diseases at the time of CM. For treatment allocation, cows were grouped by lactation number
| Treatment and randomisation
(1, >1). In every lactation number group, cows fulfilling the inclusion criteria were randomly allocated to a treatment group based on a randomization list and therapy applied following strict asepsis by trained farm personnel. Every farm had its own randomization list which was structured in the following way, the first affected cow meeting the inclusion criteria was assigned to the treatment group AB, the second cow was allocated to the treatment group ABMV, the third cow received solely Masti Veyxym ® , and the fourth cow commenced again with the treatment group AB and so on. Cows with CM in more than one quarter were also eligible for inclusion in the study, and all affected quarters received the same therapy.
| Flow of events for a cow in the study
Every month, a list containing eligible cows from every farm was pre- 
| Blinding
It was not possible to blind either the study personnel or the farmers/ herdspersons to product administration by virtue of the differences in treatment regimens. The personnel at the laboratory culturing for mastitis pathogens was unaware of the treatment given to the quarter being sampled.
| Laboratory procedure
All milk samples were collected aseptically and were stored below 
| Outcome variables
Primary outcomes were clinical cure (CC) and no CM recurrence within 60 days after the end of treatment (no R60). Secondary out- 
| Statistical analysis
The data were collected and analysed using Excel, Office 2010 For CC, no R60 and BC, the model was used to calculate leastsquare means of the various treatment groups. Thereby, the differences between treatments were estimated. Confidence intervals of the therapy differences were calculated utilising the least-square means and the standard deviation .
| RESULTS
| Descriptive results
The time frame for data collection ranged from September 2014 to September 2015. The study was conducted on eight free-stall dairy farms located in Eastern Germany. All farms were conventional and commercially oriented with a herd size between approximately 140
and 800 lactating Holstein-Friesian dairy cows. The milk production ranged from 8,000 and 9,700 kg/cow/year with bulk milk SCC (BMSCC) between 181,000 and 382,000 cells/ml. All farms were equipped with modern milking systems and used common hygiene management methods. Milkers wore gloves during milking, used one tissue per cow to clean the teats before milking and utilized teat disinfection after milking. All herds were milked twice a day, except on one farm where the high-yielding and fresh cow group was milked three times a day. A rotary milking parlour was installed on five farms, three farms milked with a herringbone parlour and no automatic milking system was present. All cows were fed with total mixed rations.
In total, 174 CM cases were enrolled in the study and no adverse events of treatment were observed. The median of lactation number for all CM cases amounted to 2 (minimum 1; maximum 6), of CSCC last DHI before CM onset 594,000 cells/ml (minimum 16,000 cells/ ml; maximum 9,694,000 cells/ml) and of milk yield last DHI before received solely intramammary antibiotic therapy, and in 25.4% of CM cases, combined intramammary and systemic antibiotic treatment was applied.
Foremilk samples of the affected quarters at CM occurrence were available in 169 cases, the remaining five samples forgotten to be taken by the milkers. The results of bacteriological culture are presented in 
| Homogeneity of treatment groups
No significant differences between treatment groups in DIM and pathogen-cultured pretreatment were found (p > .2). Treatment was allocated at herd level and at the lactation number level grouped in lactation number 1 and >1. For good measure, herd as random effect, DIM, lactation number and pathogen-cultured pretreatment were included in the generalized linear mixed models to take these factors into account.
| Clinical cure
The overall CC rate was 62.6% (109/174). The probability of CC in the AB group was 62.7% (37/59), in the ABMV group 63.5% (40/63) and in the MV group 61.5% (32/52), respectively.
Results of the generalized linear mixed model showed least-square means of 63.8% for the AB group, 62.2% for the ABMV group and 58.3% for the MV group. However, no significant differences in CC of the reference treatment AB to the test treatment MV (p = .61) and to the test treatment ABMV (p = .875) were found (Table 3) . Cows suffering from CM within 101-200 DIM showed a significantly lower probability of CC than cows affected with CM over 200 DIM (p = .023). The point estimate of the calculated differences in CC from the logistic regression and the associated 95% CI is shown in Figure 1 .
Noninferiority is inconclusive for both test treatments in comparison
with the reference treatment.
| No recurrence 60 days
Only quarters with clinically cured cases of cows, which were still in milk 60 days after the end of treatment, were included in this analysis (Pinzón-Sánchez & Ruegg, 2011 (Table 4) . Cows suffering from CM in the first lactation (p = .026) and in the second lactation (p = .009) showed a significantly higher probability of no R60 than cows affected with CM in the third or higher lactation. and to the test treatment ABMV (p = .570) were found (Table 5 ).
| Bacteriological cure
Cows suffering from CM within 101-200 DIM showed a significantly lower probability of BC than cows affected with CM over 200 DIM (p = .002). The point estimate of the calculated differences in BC from the logistic regression and the associated 95% CI is shown in Figure 1 .
Noninferiority is inconclusive for both test treatments in comparison
| Quarter somatic cell count cure
Overall twelve CM cases were excluded from this analysis due to missing post-treatment samples (seven cases) or the cow was driedoff (three cases) or slaughtered (one case) or suffered from a teat injury (one case) before at least the first post-treatment sample was collected. The pretreatment CSCC and the course of QSCC for the examined treatment groups are shown in Table 6 . The overall QSCC cure was 9.88% (16/162). Including the important covariates of the aforementioned generalized linear mixed model, there are no significant differences between the investigated treatment groups for the outcome variable QSCC cure (p = .159; data not shown).
| DISCUSSION
The main aim of this study was to evaluate the efficacy of a nonanti- Regarding CC as one primary outcome, descriptive results showed small differences in cure rates ranging from 62.7% for the reference treatment (AB) to 63.5% for ABMV and 61.5% for the nonantibiotic treatment. This is in accordance with further investigations, which reported a probability of CC of approximately 60% for CM cases treated with antibiotics, respecting different definitions of CC Swinkels et al., 2014) . The small variations in CC rates were T A B L E 3 Final mixed logistic regression model results for the primary outcome variable clinical cure. Three different treatment regimens were investigated: MV, solely Masti Veyxym®, comprising three treatments at an interval of 12 hr; ABMV, antibiotic treatment as usual on the farm according to label of the respective product combined with Masti Veyxym®, comprising three treatments at an interval of 12 hr; AB, antibiotic treatment as usual on the farm according to label of the respective product confirmed by statistical analysis, showing no significant differences for the two test treatments in comparison with the reference treatment (Table 3) . Noninferiority was inconclusive, because the CI spans both the noninferiority margin (−∆) and 0 (Figure 1 ). An inconclusive result could possibly occur due to a wide range of the CI. A method to reduce this range is to increase sample size. The noninferiority margin also influences the outcome and was chosen according to previous CM trials (Deluyker et al., 1999; Schukken & Deluyker, 1995; Schukken et al., 2013) . Sample size was calculated to give the study sufficient power and to show a difference between test and reference therapy if there was a real difference of at least 15% according to Schukken et al. (2013) . The nonantibiotic treatment showed a numerically almost identical CC rate and no significant differences to the reference treatment; noninferiority was inconclusive due to the lack of power.
The other primary outcome variable was no R60. The probability of achieving no CM recurrence within 60 days after the end of treatment was almost numerically identical for AB (53.6%) and MV (52.2%). Statistical analysis showed no significant differences between these two treatments. Noninferiority was inconclusive because the CI showed a very wide range and spans −∆ and 0. Recurrences were observed only for clinically cured cases, and some cows dropped out due to the fact that they were not in milk until 60 days after the end of treatment. Hence, the amount of evaluable cases was low and the CI increased. The no R60 rate of ABMV (65.7%) was numerically better than the rate of the reference product; only a tendency but no significant differences was shown (p = .087; Table 4 ). The CI of the difference between these two treatments spanned only 0; thus, ABMV is noninferior to the solely antibiotic therapy (Figure 1 ). In a previous study, Pinzón-Sánchez and Ruegg (2011) reported an overall nonrecurrence rate of approximately 80% within 60 days. That value is much higher than the overall no R60 rate of this study (58.1%), although they used the recurrence definition on cow level expecting actually a lower nonrecurrence rate in contrast to the quarter level used in this study. A reason could be that in this study, only cows with a longer lasting high CSCC and with previous CM cases were included. CM is a disease with recurrent character (Schukken, Bar, Hertl, & Gröhn, 2010), and Cha et al. (2016) showed that a cow with two CM cases in current lactation had a higher risk of contracting a third case. Therefore, the low overall no R60 rate could be an indication that the used eligibility criteria are able to select cows with a higher recurrence rate as previously intended.
Bacteriological cure was investigated as secondary outcome because a poor probability of BC for included CM cases was expected.
This study resulted in much lower BC rates for CM cases treated with antibiotics (AB group 37.2%; ABMV group 39.1%) in comparison with other studies, which showed a BC rate of approximately 70% Swinkels et al., 2014) . The high differences in BC rates support the selection criteria used in this study to choose cows suffering from CM with a low likelihood of BC. Nevertheless, a tendency for the efficacy of antibiotic treatment against mastitis pathogens was shown. The probability of BC in the nonantibiotic treatment group (MV) was 27.5% and therefore numerically lower than the BC rate in the reference treatment group. However, there were no significant differences between MV and AB group (p = .151).
Noninferiority was inconclusive because CI spans both −∆ and 0. This may be due to the fact that the real difference not being higher than the observed 15%. Between the ABMV and AB group were small numerical differences without significant associations and noninferiority was inconclusive.
The evaluations of noninferiority resulted mostly in inconclusive findings. A larger sample size in all treatment groups is required to confirm the detected results of the study and to make a clear statement on noninferiority.
The main interests of the farmers are disappearance of clinical signs, a low recurrence rate and a short time of discarding milk (Ruegg, 2010) . With respect to the primary outcomes, Masti Veyxym ® seems to show similar results in comparison with the reference group treated with antibiotics. Furthermore, advantageous properties of Masti Veyxym ® are the short withdrawal period for milk of 1 day, which decreases time of discarding milk, and that it contains no antibiotics, resulting in a reduced risk of residues and improved safety.
Another interesting outcome variable for farmers assessing a successful treatment is the course of the CSCC, because it is used as a measure of milk quality. In this study, cows with persistent high CSCC were chosen and a low probability of BC was expected and confirmed.
F I G U R E 1 Main results of this noninferiority trial. Black point presents point estimate of difference in outcome variables between the test treatments (MV; ABMV) and the reference treatment (AB) with the associated 95% CI indicated by the arrowheads. Dark field represents area of noninferiority. Clinical cure = difference in CC between test treatments MV (A) and ABMV (B) in comparison with AB group, the CI spans both 0 and noninferiority margin (−∆), noninferiority is inconclusive and there are no significant differences between the two treatments. No recurrence 60 days = difference in no R60 between test treatments MV (C) and ABMV (D) in comparison with AB group. C: The CI spans both 0 and −∆, noninferiority is inconclusive and there are no significant differences between the two treatments. D: The CI spans 0 but not −∆, noninferiority is proven and there are no significant differences between the two treatments. Bacteriological cure (BC) = difference in BC between test treatments MV (E) and ABMV (F) in comparison with AB group, the CI spans both 0 and −∆, noninferiority is inconclusive and there are no significant differences between the two treatments The antibiotic treatment can only affect the BC and at best eliminate the causing pathogen. Only in the successful case of BC can be achieved a CC and a noticeable reduction in CSCC (Degen et al., 2015) .
Overall, only 9.88% of the examined CM cases reached a QSCC cure and no significant differences between the treatment groups were observed. This percentage is lower than results of a recently published study of Swinkels et al. (2014) . They showed an overall QSCC cure of 22%, which suggests that a cow with the used selection criteria for this study has got a very low probability to recover a normal SCC in the affected udder quarter. The low QSCC cure rate by a CC rate of approximately 60% indicates that the observed CM cases may convert into a subclinical stage with still elevated QSCC.
Our intention was to reflect the situation in daily practice on dairy farms. That implies no information about the causative pathogen at the time of CM treatment. Therefore, and because power calculations were made on overall therapy level, evaluations of treatment efficacy at a pathogen level gave no reliable results due to lack of power.
Moreover, farmers were allowed to use their normal mastitis treatment procedure. That resulted in a wide range of used antibiotics with different durations of treatment and withholding periods. However, there were no indications of the various therapies affecting the study results.
No completely untreated control group was included in our investigation. There are some reasons for this. Clinical mastitis is a disease which is accompanied with pain, suffering and harm for the cow. Therefore, solely for reasons of the animal welfare a treatment is indicated. The participated farms were all geared to economic principles and in the normal production cycle. It was not possible to leave cows with CM untreated without any evidence-based information. Furthermore, they mostly did not differentiate between a first CM case and a chronic mastitis, all CM cases were treated with antibiotics. Finally, prior to the study we were unaware if the chosen selection criteria for cows are really suitable to identify cows with CM expecting a poor probability of BC.
| CONCLUSIONS
A randomized, multiherd, noninferiority study was conducted evalu- and noninferiority compared to the reference treatment was proven.
The study findings indicate that using solely Masti Veyxym ® in treatment of mild-to-moderate CM in cows with longer lasting udder diseases may constitute an alternative therapy to reduce antibiotics. However, to give a reliable noninferiority evaluation, a higher sample size is needed. The selection criteria of cows have to be respected, and it is recommended to remove such animals from the herd if possible.
